 SALT LAKE CITY, Sept. 23, 2021 GLOBE NEWSWIRE -- Clene Inc. NASDAQ: CLNN along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat cellular energetic failure, announced the launch of a second U.S. Food and Drug Administration FDA expanded access program CNMAu8.EAP02 with CNM-Au8 for people living with amyotrophic lateral sclerosis ALS. 